Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features (Q36194635)

12 August 2017

1 reference

title

Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features (English)

1 reference

12 August 2017

chronic myeloid leukemia

0 references

1 reference

Klaus Eisendle

1

1 reference

12 August 2017

Dominik Wolf

series ordinal

2

1 reference

12 August 2017

Guenther Gastl

series ordinal

3

1 reference

12 August 2017

Brigitte Kircher-Eibl

series ordinal

4

1 reference

12 August 2017

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

46

1 reference

12 August 2017

5

1 reference

12 August 2017

663-670

1 reference

Chronic myelogenous leukaemia

12 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Dendritic cells and their potential therapeutic role in haematological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Dendritic cells: specialized and regulated antigen processing machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Dendritic cell immunotherapy: mapping the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

The pathophysiology of tumor necrosis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Optimisation of the conditions for generating human DC initiated antigen specific T lymphocyte lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Specific targeted therapy of chronic myelogenous leukemia with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

MAP kinases in the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Expression of relB is required for the development of thymic medulla and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-α

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190400029825

10.1080/10428190400029825

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference